Hyponatremia is associated with an increased risk of death. The economic costs of hyponatremia are estimated at $2.6 billion in the United States. Signs and symptoms of hyponatremia include nausea and vomiting, headache, short-term memory loss, confusion, lethargy, fatigue, loss of appetite, irritability, muscle weakness, spasms or cramps, seizures, and decreased consciousness or coma. The presence and severity of signs and symptoms are related to the level of salt in the blood, with lower levels of plasma sodium associated with more severe symptoms. However, emerging data suggest that mild hyponatremia (plasma sodium levels at 131–135 mmol/L) is associated with numerous complications
Serum (blood) toxic response. Blood is centrifuged to remove cellular components. Anti-coagulated blood yields plasma containing fibrinogen and clotting factors. Coagulated blood (clotted blood) yields serum without fibrinogen, although some clotting factors remain. Serum is an essential factor for the self-renewal of embryonic stem cells in combination with the cytokine leukemia inhibitory factor. The serum of convalescent patients successfully recovering (or already recovered) from an infectious disease can be used as a biopharmaceutical in the treatment of other people with that disease, because the antibodies generated by the successful recovery are potent fighters of the pathogen. Such "convalescent serum" (antiserum) is a